Apollomics, Inc., a biotechnology company, engages in the discovery and development of mono and combination oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. Its pipeline consists of various development-stage assets, including novel and humanized monoclonal antibodies that restore the body's immune system to recognize and kill cancer cells, and targeted therapies against uncontrolled growth signaling pathways. Its solutions include tumor inhibitors, anti-cancer enhancers, and immune-oncology drugs. Apollomics, Inc. was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. Apollomics, Inc. was incorporated in 2016 and is based in Foster City, California with additional locations in Hangzhou and Shanghai, China and Southbank, Australia.
Frequently asked questions
What sector does Apollomics Inc. Warrant (APLMW) operate in?
Apollomics Inc. Warrant belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Apollomics Inc. Warrant (APLMW) current stock price?
As of the latest data, Apollomics Inc. Warrant stock price is $0.02, with a previous close of $0.02. Apollomics Inc. Warrant lost -$0.00 in the last trading session, representing a -0.55% loss.
What is Apollomics Inc. Warrant (APLMW) current market capitalization?
Apollomics Inc. Warrant market cap is approximately 44.88 million.
What is Apollomics Inc. Warrant (APLMW) EBITDA?
Apollomics Inc. Warrant EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is 3.03 million.
Does Apollomics Inc. Warrant (APLMW) pay dividends?
No. Apollomics Inc. Warrant does not pay a dividend.
What is Apollomics Inc. Warrant (APLMW) beta (volatility) score?
Apollomics Inc. Warrant has a beta of 0.595, indicating lower volatility than the overall market.
